Västra Hamnen Corporate Finance has released a research update on Scandinavian ChemoTech following its report for Q1 2019. Orders were impressive while sales were disappointing. On the whole, our valuation range remains intact.
· Four IQwave™ units ordered in Q1, a new record
· Sales were disappointing in the quarter
· CE mark awarded in Q3 at the earliest
In the Q1 report last week, Scandinavian ChemoTech summed up its best quarter so far in terms of number of IQwave™ units ordered. Revenues were however surprisingly low compared with recent quarters. Comparing the accounts for Q1